ABEONA THERAPEUTICS INC. Lease, Cost
ABEONA THERAPEUTICS INC. (ABEO) reported Lease, Cost of $454.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. lease, cost for the quarter ending 2026-06-30 was $454.00K, a 3.40% decline year-over-year.
- ABEONA THERAPEUTICS INC. lease, cost for the quarter ending 2026-03-31 was $478.00K, a 3.63% decline year-over-year.
- ABEONA THERAPEUTICS INC. lease, cost for the quarter ending 2025-12-31 was $382.00K, a 6.60% decline year-over-year.
- ABEONA THERAPEUTICS INC. lease, cost for the quarter ending 2025-09-30 was $520.00K, a 25.00% increase year-over-year.
- ABEONA THERAPEUTICS INC. lease, cost for fiscal 2025 was $1.87M, a 8.79% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. lease, cost for fiscal 2024 was $1.72M, a 5.14% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. lease, cost for fiscal 2023 was $1.81M, a 23.89% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. lease, cost for fiscal 2022 was $2.38M, a 0.46% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $454.00K 10-Q · filed 2026-08-13 | $932.00K 10-Q · filed 2026-08-13 | $1.31M derived: sum of 3 quarters · filed 2026-08-13 | $1.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $478.00K 10-Q · filed 2026-05-13 | $860.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.38M derived: sum of 3 quarters · filed 2026-05-13 | $1.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $902.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.37M derived: sum of 3 quarters · filed 2026-08-13 | $1.87M 10-K · filed 2026-03-17 |
| 2025-09-30 | $520.00K 10-Q · filed 2025-11-12 | $990.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.49M 10-Q · filed 2025-11-12 | $1.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $470.00K 10-Q · filed 2026-08-13 | $966.00K 10-Q · filed 2026-08-13 | $1.38M derived: sum of 3 quarters · filed 2026-08-13 | $1.79M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $496.00K 10-Q · filed 2026-05-13 | $905.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.32M derived: sum of 3 quarters · filed 2026-05-13 | $1.78M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $825.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.29M derived: sum of 3 quarters · filed 2026-03-17 | $1.72M 10-K · filed 2026-03-17 |
| 2024-09-30 | $416.00K 10-Q · filed 2025-11-12 | $877.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.31M 10-Q · filed 2025-11-12 | $1.74M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $461.00K 10-Q · filed 2025-08-14 | $892.00K 10-Q · filed 2025-08-14 | $1.32M derived: sum of 3 quarters · filed 2025-08-14 | $1.75M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $431.00K 10-Q · filed 2025-05-15 | $862.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.29M derived: sum of 3 quarters · filed 2025-05-15 | $1.77M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $856.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.34M derived: sum of 3 quarters · filed 2025-03-20 | $1.81M 10-K · filed 2025-03-20 |
| 2023-09-30 | $425.00K 10-Q · filed 2024-11-14 | $907.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.38M 10-Q · filed 2024-11-14 | $1.93M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $482.00K 10-Q · filed 2024-08-12 | $954.00K 10-Q · filed 2024-08-12 | $1.51M derived: sum of 3 quarters · filed 2024-08-12 | $2.15M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $472.00K 10-Q · filed 2024-05-15 | $1.03M derived: sum of 2 quarters · filed 2024-05-15 | $1.66M derived: sum of 3 quarters · filed 2024-05-15 | $2.26M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $554.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $1.19M derived: sum of 2 quarters · filed 2024-03-18 | $1.79M derived: sum of 3 quarters · filed 2024-03-18 | $2.38M 10-K · filed 2024-03-18 |
| 2022-09-30 | $638.00K 10-Q · filed 2023-11-13 | $1.24M derived: sum of 2 quarters · filed 2023-11-13 | $1.82M 10-Q · filed 2023-11-13 | $2.54M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $597.00K 10-Q · filed 2023-08-08 | $1.19M 10-Q · filed 2023-08-08 | $1.91M derived: sum of 3 quarters · filed 2023-08-08 | $2.46M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $589.00K 10-Q · filed 2023-05-11 | $1.31M derived: sum of 2 quarters · filed 2023-05-11 | $1.86M derived: sum of 3 quarters · filed 2023-05-11 | $2.40M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $720.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.27M derived: sum of 2 quarters · filed 2023-03-29 | $1.81M derived: sum of 3 quarters · filed 2023-03-29 | $2.39M 10-K · filed 2023-03-29 |
| 2021-09-30 | $552.00K 10-Q · filed 2022-11-14 | $1.09M derived: sum of 2 quarters · filed 2022-11-14 | $1.67M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $543.00K 10-Q · filed 2022-08-11 | $1.12M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |